Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Accured Expenses (2017 - 2023)

Dianthus Therapeutics (DNTH) has 5 years of Change in Accured Expenses data on record, last reported at -$1.7 million in Q2 2023.

  • For Q2 2023, Change in Accured Expenses fell 169.82% year-over-year to -$1.7 million; the TTM value through Jun 2023 reached -$2.6 million, up 2.06%, while the annual FY2022 figure was $973000.0, 535.95% up from the prior year.
  • Change in Accured Expenses reached -$1.7 million in Q2 2023 per DNTH's latest filing, up from -$3.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.5 million in Q4 2022 and bottomed at -$3.3 million in Q1 2023.
  • Average Change in Accured Expenses over 3 years is -$811857.1, with a median of -$859000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: tumbled 40.91% in 2019, then crashed 288.71% in 2023.
  • A 3-year view of Change in Accured Expenses shows it stood at -$1.6 million in 2019, then soared by 192.85% to $1.5 million in 2022, then tumbled by 210.66% to -$1.7 million in 2023.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$1.7 million in Q2 2023, -$3.3 million in Q1 2023, and $1.5 million in Q4 2022.